SUMMARY OF PRODUCT CHARACTERISTICS

During a median of 18 months following discontinuation of teriparatide, there was a 41 % reduction (p=0.004) compared with placebo in the number of patients with a minimum of one

In a twelve-month, controlled clinical study in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 25 to 27 mmHg, the mean IOP-lowering effect of

Nevertheless, efficacy data in the age group 0 to < 3 years were based on only 13 patients for latanoprost and no relevant efficacy was shown from the 4 patients representing

SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN.. Keep out of the sight and reach

The overall efficacy of the bimatoprost 0.03 %/timolol 0.5 % eye drops combination in the treatment of patients with open-angle glaucoma or ocular hypertension

[r]

Fuchsjäger-Mayrl G, Wally B, Rainer G et al (2005): Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension; Br

As Bimatoprost and Timolol are not new chemical entities, this application is related to a medicinal product claiming essential similarity Ganfort® (Allergan Ltd,